- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Metasyn taps Webb as new CEO
Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Metasyn has appointed Michael D. Webb as president and CEO ofthe privately held Cambridge, MA, contrast agent developer. Webbassumes the chief executive position from Metasyn founder RandallB. Lauffer, who will remain chair and chief scientific officer.
Webb comes to Metasyn from Ciba-Corning Diagnostics, wherehe was senior vice president of worldwide marketing and strategicplanning.
The appointment of Webb represents a step in the company'seffort to commercialize its products, which are in advanced preclinicalstudies, according to the firm. Metasyn is developing MS-323,an MRI blood-pool agent that binds reversibly to albumin.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
